[Clinical evaluation of serum immunosuppressive acidic protein (IAP) and acid soluble glycoproteins (ASP) in patients with malignant tumors]. 1989

K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa

In order to study the clinical significance of IAP and ASP, we have measured serum concentration of IAP and ASP in patients with different cancer types including digestive organs, head and neck. Significantly higher correlation (coefficient of correlation = 0.924) was found between IAP and ASP. IAP and ASP levels were elevated in about 60-80% of cancer from digestive organs except hepatocellular carcinoma, and in about 56-100% of head and neck tumor. There was no correlation between IAP, ASP and various tumor markers (CEA, CA19-9, AFP) in all malignancies except pancreatic cancer. There was positive correlation between CEA and IAP, ASP in pancreatic cancer. IAP and ASP levels were significantly higher in patients with cancer having evidence of disease than the patients with cancer who had no evidence of disease, and so the determination of IAP and ASP was clinically useful for the diagnosis of tumor existence. At the time of diagnosis of recurrence, the levels of IAP and ASP were elevated in about 70% of patients with cancer recurrence. There was a definite relation between IAP, ASP and the gastric cancer stage. In later state (stage III and IV), serum IAP and ASP levels were significantly higher than the levels of stage I and II. In hepatocellular carcinoma without liver cirrhosis, the levels of IAP and ASP were higher than the patients with cirrhosis. The determination of IAP and ASP seems to be useful for monitoring clinical course, judgement of therapeutic effects.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D005770 Gastrointestinal Neoplasms Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. Gastrointestinal Cancer,Cancer of Gastrointestinal Tract,Cancer of the Gastrointestinal Tract,Neoplasms, Gastrointestinal,Cancer, Gastrointestinal,Cancers, Gastrointestinal,Gastrointestinal Cancers,Gastrointestinal Neoplasm,Gastrointestinal Tract Cancer,Gastrointestinal Tract Cancers,Neoplasm, Gastrointestinal
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
January 1985, Auris, nasus, larynx,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
December 1986, Rinsho byori. The Japanese journal of clinical pathology,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
September 1986, Gan no rinsho. Japan journal of cancer clinics,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
October 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
June 1985, Nihon Sanka Fujinka Gakkai zasshi,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
March 1986, Bulletin of the Chest Disease Research Institute, Kyoto University,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
July 1990, Nippon Ganka Gakkai zasshi,
K Shibasaki, and K Soga, and M Toshima, and K Aikawa, and T Tsuruya, and T Itoh, and Y Takahashi, and M Tsuchimochi, and I Mataga, and K Tsuchikawa
February 1983, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!